Title:	Integrative transcriptomic and functional analysis of pkmyt1 reveals a potential therapeutic target in chronic lymphocytic leukemia
Authors:	Bispo, Elizabete Cristina Iseke Pontes, Cláudia de Souza Lima Nascimento, Jennifer Martins do Alves, Fábio Wilson de Lima Carvalho, Juliana Lott de Araujo, Antônio Roberto Lucena Araujo, Felipe Saldanha
metadata.dc.identifier.orcid:	https://orcid.org/0000-0002-4200-0821
metadata.dc.contributor.affiliation:	Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Hematologia e Células‐Tronco Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Hematologia e Células‐Tronco Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Hematologia e Células‐Tronco Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Hematologia e Células‐Tronco Universidade de Brasília, Faculdade de Medicina, Laboratório de Biociências Universidade Federal de Pernambuco, Centro de Biociências, Laboratório de Hematologia Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Hematologia e Células‐Tronco
Assunto::	Leucemia linfocítica crônica (LLC) Instabilidade genômica Regulação do ciclo celular
Issue Date:	Jul-2026
Publisher:	Wiley
Citation:	BISPO, Elizabete Cristina Iseke; PONTES, Cláudia de Souza Lima; NASCIMENTO, Jennifer Martins do; ALVES, Fábio Wilson de Lima; CARVALHO, Juliana Lott de; ARAUJO, Antônio Roberto Lucena; ARAUJO, Felipe Saldanha. Integrative transcriptomic and functional analysis of pkmyt1 reveals a potential therapeutic target in chronic lymphocytic leukemia. Hematological Oncology, v. 44, n. 4, 2026. DOI: https://doi.org/10.1002/hon.70208. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/hon.70208. Acesso em: 12 ago. 2026.
Abstract:	Chronic lymphocytic leukemia (CLL) is a clinically and molecularly heterogeneous disease. PKMYT1, a G2/M cell cycle kinase, has been implicated in tumor progression in several cancers, but its role in CLL remains unclear. We evaluated PKMYT1 expression in primary CLL samples and analyzed associations with cytogenetic features and clinical parameters. PKMYT1 expression was heterogeneous and correlated with adverse features, including complex karyotype and elevated leukocyte counts. Comparative transcriptomic analyses between high‐ and low‐expression groups revealed enrichment of pathways related to chromatin remodeling, DNA repair, and mitotic regulation. In MEC1 cells, pharmacological PKMYT1 inhibition significantly reduced cancer cell viability. PCR analysis showed upregulation of TP53, CASP3, BAK, GSDMD, BCL2, CASP1, IL1β, RIPK1, and RIPK3 , indicating activation of apoptotic, inflammasome‐associated, and necroptotic pathways. Collectively, these findings demonstrate that PKMYT1 is heterogeneously expressed in CLL, associated with adverse cytogenetic and clinical features, and critical for cell survival, highlighting its potential as a therapeutic target.
Licença::	This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
DOI:	https://doi.org/10.1002/hon.70208
Appears in Collections:	Artigos publicados em periódicos e afins

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.